Diabetes Caucus Floats Ideas To Lower Insulin Prices

November 06, 2018
The Congressional Diabetes Caucus recommended Thursday (Nov. 1) 11 policies aimed at lowering insulin prices, including a new biosimilar approval path for insulins. The bipartisan caucus wants to encourage drug companies to charge for drugs only when they work and says Congress could help by changing anti-kickback law and the Medicaid best price rule so drug makers can confidently engage in so-called value-based contracts. These ideas are also being considered by the Trump administration. Congress also could make insurers in...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.